Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab

Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of long-term survival remain elusive. We utilized the Alberta Immunotherapy Databas...

Descripción completa

Detalles Bibliográficos
Autores principales: Goutam, Siddhartha, Stukalin, Igor, Ewanchuk, Benjamin, Sander, Michael, Ding, Philip Q., Meyers, Daniel E., Heng, Daniel, Cheung, Winson Y., Cheng, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600126/
https://www.ncbi.nlm.nih.gov/pubmed/36290885
http://dx.doi.org/10.3390/curroncol29100608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600126/
https://www.ncbi.nlm.nih.gov/pubmed/36290885
http://dx.doi.org/10.3390/curroncol29100608

Ejemplares similares